Sequential Study to Treat Renal Cell Carcinoma

NCT00732914 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

272

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

DRUG: Sunitinib (Sutent)
DRUG: Sorafenib (Nexavar)

Sponsor

Sponsor GmbH

Collaborators

[object Object]